SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Michael P. N. Findlay, Jens Ricke, Marc Peeters, David Perez, Bridget Anne Robinson, Andrew Strickland, Tom Ferguson, Javier Rodriguez, Hendrik Kroening, Ido Wolf, Vinod Ganju, Euan Thomas Walpole, Eveline Boucher, Thomas E. Tichler, Val Gebski, Mark Van Buskirk, Guy A. Van Hazel
Institutions: Walter and Eliza Hall Institute of Medical Research, LMU Klinikum, Ludwig-Maximilians-Universität München, University of Maryland Medical Center, University of Auckland, Cancer Trials New Zealand, University Hospital Magdeburg, Antwerp University Hospital, Mercy Hospital, Christchurch Hospital, Monash Medical Centre, Monash Health, Royal Perth Hospital, Clinica Universidad de Navarra, Sheba Medical Center, Princess Alexandra Hospital, Centre Eugène Marquis, Shaare Zedek Medical Center, National Health and Medical Research Council, The University of Western Australia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590864037